Hanxiong (Bear) Zhang
Principal RA Capital Management
Bear Zhang is an Associate with the TechAtlas division of RA Capital Management. Bear’s primary responsibilities are to work closely with members of the investment team and portfolio companies to deeply understand competitive landscapes, evaluate investment opportunities in a variety of therapeutic areas across all stages from discovery and new company creation through commercialization, and advise portfolio companies on program and pipeline strategy. Prior to this role, he was a consultant at Clarion Healthcare. Bear holds a BSc in Biomedical Sciences from Zhejiang University and a PhD in Biological and Biomedical Sciences from Harvard University.
Seminars
Thursday 4th June 2026
Panel Discussion: Revitalizing the ALS Investment Landscape: Opportunities, Challenges, & the Path Forward
9:30 am
- What are the current barriers to investment in ALS therapeutics, and how can stakeholders address perceived scientific or clinical risks?
- Which emerging modalities or targets in ALS are attracting the most investor interest, and where do pharma companies see the greatest potential for collaboration?
- How can early-stage data, biomarkers, or patient-focused endpoints help de-risk ALS programs for investors and facilitate pharma partnerships?
- What lessons can be learned from past ALS investment successes and failures to guide more sustainable funding strategies?
- How can collaboration between VCs, corporate pharma, and patient advocacy groups accelerate both funding and development of ALS therapies?
